Solid Hits on the SPY
We try to formulate new options ideas for a given session as often as we can without forcing the issue, and on most days we produce at least one. Yesterday, we designated our sole set of new contracts to watch as the SPY Weekly $250-248 Puts, and thanks to a painful day for the markets, we were afforded the chance to score some pretty nice intraday gains.
Two out of three of those strike points translated into instant double-bag opportunities, with the third falling just 1% short of that mark, providing the following moves on the day:
SPY Weekly $250-248 Puts
$250: 4.39-8.73 (+99%)
$249: 4.00-8.10 (+103%)
$248: 3.65-7.50 (+105%)
SPY Weekly $244-242 Puts
WBA Weekly $44-45 Calls
KMX Weekly $50-55 Calls
CytoDyn, Inc. CYDY
We began tracking CYDY on Tuesday morning, and in addition to making a nominal move on the chart, the company has also put out some coronavirus related press in the couple days. One of the company’s investigational drugs which is about to enter Phase 2b/3 trials, has demonstrated a promising level of efficacy among severe COVID-19 patients.
The stock itself has run from 2.65-3.09 in the past couple of sessions, which marks a move of just 17% but we’re going to be interested to continue tracking its performance in light of the company’s announcements.
VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic bio-markers. Patient test data reveals improvement in cytokines, IL-6, and a trend toward the normalization of the CD4/CD8 ratio. (>>View Full PR)
GRYO, PNAT, ROTH, SOLI, CTYX, IPIX